We’re excited to share a new paper, published today in Nature Cancer, by our scientists in collaboration with researchers at Else Kröner Fresenius Center for Digital Health. In this paper, we explore how multimodal models (AI models that can parse different data inputs) and autonomous agents (AI systems that can perform without direct human intervention) could transform cancer research and oncology by integrating diverse data types and streamlining complex workflows. These systems have the potential to accelerate drug development, improve clinical trial design, and address complex biomedical challenges. Learn more about these perspectives on autonomous agents in cancer research: http://spr.ly/6045QaAnx #AI #DeepLearning #Oncology
About us
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
- Website
-
http://www.gene.com
External link for Genentech
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 1976
- Specialties
- Oncology, Immunology, Disorders of Tissue Growth and Repair, Neuroscience and Infectious Disease, Metabolism, and Ophthalmology
Locations
-
Primary
Get directions
1 Dna Way
South San Francisco, California 94080, US
-
Get directions
1000 New Horizons Way
Vacaville, California 95688, US
-
Get directions
1 Antibody Way
Oceanside, California 92056, US
-
Get directions
4625 NE Brookwood Pkwy
Hillsboro, Oregon 97124, US
Employees at Genentech
Updates
-
We’re proud to share that National Geographic recently recognized our food allergy medicine as one of the Top Seven Medical Breakthroughs That Gave Us Hope in 2024! Hear from Scott St. Germain, our Vice President of Respiratory as he reflects on this milestone, and how we’re honored to be part of the progress bringing hope to those affected by food allergies.
-
Each year, thousands of women are diagnosed with metastatic breast cancer, a complex disease that can also be affected by mutations like PIK3CA. Early comprehensive biomarker testing can help uncover these mutations, informing a more personalized treatment approach from the outset. Learn more: https://lnkd.in/gPbGgRZE
A Common Gene Mutation in Metastatic Breast Cancer
-
We've been named one of Computerworld’s Best Places to Work in IT for the 16th consecutive year! Whether harnessing AI to accelerate drug discovery and development, collaborating globally across teams to problem-solve for patients, or upskilling through our steady stream of training programs, our Informatics team continually redefines what’s possible with science and technology in healthcare. Congratulations to our colleagues for this incredible achievement. http://spr.ly/6041Qp0Kb #BestPlacesIT
-
-
We’re sharing new data at #ASH24 from our industry-leading CD20xCD3 T-cell engaging bispecific antibody program across different types of aggressive and indolent #lymphoma. Learn more about how we’re exploring new routes of administration and novel combinations in earlier stages of the disease: http://spr.ly/6047QRftf
-
We recently concluded Season 5 of Two Scientists Walk Into a Bar with an episode on AI and machine learning. http://spr.ly/6042QRXHs
This content isn’t available here
Access this content and more in the LinkedIn app
-
This #ASH24, we’re proud to present five-year follow-up data from our Phase III study, highlighting the potential of our antibody-drug conjugate for people with previously untreated diffuse large B-cell #lymphoma (#DLBCL). Learn more about our efforts to address disease progression: http://spr.ly/6041QMT4L
-
As Head of Computational Sciences, John Marioni has made groundbreaking contributions in the fields of biology and computational science. With an optimistic mindset, strong leadership, and a tenacious work ethic, John is driving advancements in one of the most challenging areas of science — drug discovery. Learn more about how John’s team uses computational approaches, including the “lab in a loop,” to transform drug discovery: http://spr.ly/6042thOQw
-
Richard Bae, Patient Experience Lead and Senior Director of Oncology Patient Access Services, had an instinctive feeling that something felt off with his body. After getting lab work done, he was diagnosed with diffuse large B cell lymphoma (DLBCL), a type of blood cancer. Having experienced firsthand the impact of a cancer diagnosis, Richard is proud to participate in Cancer Screen Week to remind colleagues and patients about the importance of regular cancer screenings. http://spr.ly/6045tLUBB #CancerScreenWeek
-
Meet Melanie Heinlein, a Postdoctoral Fellow in Oncology from Germany. Her research focuses on intestinal cancer and understanding the mechanisms that allow cancer cells to migrate from primary tumor sites to distant organs and establish metastasis. Melanie’s passion for basic science is what brought her to our company. She hopes to continue translating research from bench to bedside. Check out her scientific pursuits in the video below and learn more about our Postdoctoral programs. http://spr.ly/6043QEkqZ
Learn more about our Postdoctoral programs